Research
Hormonal
GIP receptor antagonists can promote weight loss in non-human primates and rodents, challenging the view that GIP promotes obesity.
Blocking GIP receptors (antagonism) has been shown to reduce weight gain in animal models, suggesting that endogenous GIP may play a role in promoting obesity. This supports the development of GIP antagonists for weight management.
ModerateSupportsMEDIUM confidence
Amgen, presented preclinical data from non-human primates showing that a GIP receptor antagonist (a monoclonal antibody), both alone and in combination with GLP-1, effectively reduced the normal increase in body weight in obese animals.
Why this rating
Based on preclinical animal data, not human trials.
Source
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Jens J. Holst et al. · The Journal of Clinical Endocrinology & Metabolism · 2020
DOI 10.1210/clinem/dgaa327
narrative_reviewCited 191×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GIP-GLP-1 co-agonists (e.g., tirzepatide) produce superior weight loss and glycemic control compared to GLP-1 receptor agonists alone in patients with type 2 diabetes and obesity.Good
- The efficacy of GIP-GLP-1 co-agonists may be explained by biased agonism and altered receptor internalization, which prevents the desensitization seen with pure GIP agonists.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →